Overview

Efficacy and Safety of Itolizumab in COVID-19 Complications

Status:
Completed
Trial end date:
2020-07-07
Target enrollment:
Participant gender:
Summary
Randomized, Parallel Group, Active Controlled Trial
Phase:
Phase 2
Details
Lead Sponsor:
Biocon Limited
Treatments:
Anti-Bacterial Agents
Antiviral Agents
Hydroxychloroquine